^
    25d
    Predicting homologous recombination deficiency and treatment responses using a computed tomography-based foundation model: a preclinical study. (PubMed, NPJ Precis Oncol)
    Interpretability analysis indicated the important role of texture heterogeneity in HRD classification. Therefore, these results suggest that FM successfully overcomes the data scarcity in animal studies and enables HRD classification and treatment response prediction from preclinical CT imaging.
    Preclinical • Journal
    |
    HRD (Homologous Recombination Deficiency)
    |
    HRD
    |
    CP-506
    5ms
    Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI (clinicaltrials.gov)
    P1/2, N=126, Recruiting, Maastricht University Medical Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    MSK-IMPACT
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc) • CP-506
    almost3years
    Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI (clinicaltrials.gov)
    P1/2, N=126, Recruiting, Maastricht University | Not yet recruiting --> Recruiting
    Enrollment open • Pan tumor
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    MSK-IMPACT
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc) • CP-506
    over3years
    Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI (clinicaltrials.gov)
    P1/2, N=126, Not yet recruiting, Maastricht University | Trial completion date: Oct 2025 --> May 2026 | Trial primary completion date: Sep 2025 --> Feb 2026
    Trial completion date • Trial primary completion date • Pan tumor
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc) • CP-506
    almost4years
    Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI (clinicaltrials.gov)
    P1/2, N=126, Not yet recruiting, Maastricht University | Trial completion date: Oct 2024 --> Oct 2025 | Initiation date: Oct 2021 --> Jun 2022 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial initiation date • Trial primary completion date • Pan tumor
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc) • CP-506
    over4years
    Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI (clinicaltrials.gov)
    P1/2, N=126, Not yet recruiting, Maastricht University
    Clinical • New P1/2 trial • Pan tumor
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc) • CP-506